{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:40:36Z","timestamp":1774572036416,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Bacteriophage (phage) therapy is emerging as a promising alternative to traditional antibiotics for treating drug-resistant mycobacterial infections, including Mycobacterium tuberculosis complex (MTBC) and non-tuberculous mycobacteria (NTM) [...]<\/jats:p>","DOI":"10.3390\/idr17020024","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:55:44Z","timestamp":1741755344000},"page":"24","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phage Therapy for Mycobacteria: Overcoming Challenges, Unleashing Potential"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6676-5431","authenticated-orcid":false,"given":"Christoffel Johannes","family":"Opperman","sequence":"first","affiliation":[{"name":"National Health Laboratory Service, Green Point TB-Laboratory, Cape Town 8005, South Africa"},{"name":"SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Stellenbosch University, Cape Town 7505, South Africa"},{"name":"Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-9690","authenticated-orcid":false,"given":"Adrian J.","family":"Brink","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Green Point TB-Laboratory, Cape Town 8005, South Africa"},{"name":"Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa"},{"name":"Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pmbts.2023.03.016","article-title":"Phages for the treatment of Mycobacterium species","volume":"201","author":"Opperman","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_2","first-page":"346","article-title":"Treating bacterial infections with bacteriophages in the 21st century","volume":"37","author":"Opperman","year":"2022","journal-title":"S. Afr. J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zeynali Kelishomi, F., Khanjani, S., Fardsanei, F., Saghi Sarabi, H., Nikkhahi, F., and Dehghani, B. (2022). Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: A review. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07944-9"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jia, H.J., Jia, P.P., Yin, S., Bu, L.K., Yang, G., and Pei, D. (2023). Engineering bacteriophages for enhanced host range and efficacy: Insights from bacteriophage-bacteria interactions. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1172635"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/eva.13518","article-title":"Comparison of bacterial suppression by phage cocktails, dual-receptor generalists, and coevolutionarily trained phages","volume":"16","author":"Borin","year":"2022","journal-title":"Evol. Appl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41564-024-01712-y","article-title":"Personalized bacteriophage therapy for difficult-to-treat infections","volume":"9","author":"Iredell","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Abdelkader, K., Guti\u00e9rrez, D., Tam\u00e9s-Caunedo, H., Ruas-Madiedo, P., Safaan, A., Khairalla, A.S., Gaber, Y., Dishisha, T., and Briers, Y. (2022). Engineering a lysin with intrinsic antibacterial zctivity (LysMK34) by cecropin A fusion enhances its antibacterial properties against Acinetobacter baumannii. Appl. Environ. Microbiol., 88.","DOI":"10.1128\/AEM.01515-21"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Khan, F.M., Rasheed, F., Yang, Y., Liu, B., and Zhang, R. (2024). Endolysins: A new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1385261"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yang, Q., Le, S., Zhu, T., and Wu, N. (2023). Regulations of phage therapy across the world. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1250848"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.copbio.2020.12.018","article-title":"Phage biobank: Present challenges and future perspectives","volume":"68","author":"Lin","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: Compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1093\/cid\/ciad515","article-title":"Use of bacteriophages to target intracellular pathogens","volume":"77","author":"Venturini","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Klumpp, J., Dunne, M., and Loessner, M.J. (2023). A perfect fit: Bacteriophage receptor-binding proteins for diagnostic and therapeutic applications. Curr. Opin. Microbiol., 71.","DOI":"10.1016\/j.mib.2022.102240"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"113864","DOI":"10.1016\/j.addr.2021.113864","article-title":"Formulation strategies for bacteriophages to target intracellular bacterial pathogens","volume":"176","author":"Yan","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Davis, N.K., Chionh, Y.H., McBee, M.E., Hia, F., Ma, D., Cui, L., Sharaf, M.L., Cai, W.M., Jumpathong, W., and Levine, S.S. (2024). Facile metabolic reprogramming distinguishes mycobacterial adaptation to hypoxia and starvation: Ketosis drives starvation-induced persistence in M. bovis BCG. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-06562-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-virology-091919-074551","article-title":"Bacteriophages and the immune system","volume":"8","author":"Popescu","year":"2021","journal-title":"Annu. Rev. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","article-title":"Phage therapy for nontuberculous mycobacteria: Challenges and opportunities","volume":"9","author":"Hatfull","year":"2023","journal-title":"Pulm. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Allu\u00e9-Guardia, A., Garcia-Vilanova, A., Olmo-Font\u00e1nez, A.M., Peters, J., Maselli, D.J., Wang, Y., Turner, J., Schlesinger, L.S., and Torrelles, J.B. (2022). Host- and age-dependent transcriptional changes in Mycobacterium tuberculosis cell envelope biosynthesis genes after exposure to human alveolar lining fluid. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020983"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Segura-Cerda, C.A., L\u00f3pez-Romero, W., and Flores-Valdez, M.A. (2019). Changes in host response to Mycobacterium tuberculosis infection associated with type 2 diabetes: Beyond hyperglycemia. Front. Cell Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00342"}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/17\/2\/24\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:57Z","timestamp":1760028657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/17\/2\/24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["idr17020024"],"URL":"https:\/\/doi.org\/10.3390\/idr17020024","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}